WallStreetZenWallStreetZen

NASDAQ: AFMD
Affimed Nv Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AFMD

Based on 3 analysts offering 12 month price targets for Affimed Nv

Min Forecast
$4.00+444.96%
Avg Forecast
$9.67+1,217.03%
Max Forecast
$15.00+1,943.6%

Should I buy or sell AFMD stock?

Based on 3 analysts offering ratings for Affimed Nv.

Buy
Strong Buy
1 analysts 33.33%
Buy
1 analysts 33.33%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AFMD stock forecasts and price targets.

AFMD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-12-12
lockedlocked$00.00+00.00%2024-12-10
lockedlocked$00.00+00.00%2024-11-15

1 of 1

Forecast return on equity

Is AFMD forecast to generate an efficient return?

Company
-47.49%
Industry
147.61%
Market
81.79%
AFMD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AFMD forecast to generate an efficient return on assets?

Company
-20.44%
Industry
35.5%
AFMD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AFMD earnings per share forecast

What is AFMD's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$2.05
Avg 2 year Forecast
-$0.81
Avg 3 year Forecast
-$0.63

AFMD revenue forecast

What is AFMD's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$2.1M+118.59%
Avg 2 year Forecast
$3.2M+223.26%
Avg 3 year Forecast
$13.9M+1,331.07%
AFMD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AFMD revenue growth forecast

How is AFMD forecast to perform vs Biotechnology companies and vs the US market?

Company
140.43%
Industry
65.42%
Market
10.41%
AFMD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AFMD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AFMD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AFMD$0.73$9.67+1,217.03%Buy
MBRX$0.88$6.00+585.71%Strong Buy
MRKR$1.15$13.17+1,044.96%Strong Buy
SYBX$1.06N/AN/A
NRXS$1.60N/AN/A
View Top Biotech Stocks

Affimed Nv Stock Forecast FAQ

Is Affimed Nv Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: AFMD) stock is to Buy AFMD stock.

Out of 3 analysts, 1 (33.33%) are recommending AFMD as a Strong Buy, 1 (33.33%) are recommending AFMD as a Buy, 1 (33.33%) are recommending AFMD as a Hold, 0 (0%) are recommending AFMD as a Sell, and 0 (0%) are recommending AFMD as a Strong Sell.

If you're new to stock investing, here's how to buy Affimed Nv stock.

What is AFMD's earnings growth forecast for 2025-2027?

(NASDAQ: AFMD) Affimed Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.28%.

Affimed Nv's earnings in 2025 is -$74,436,170.On average, 3 Wall Street analysts forecast AFMD's earnings for 2025 to be -$33,550,208, with the lowest AFMD earnings forecast at -$49,504,876, and the highest AFMD earnings forecast at -$17,211,960. On average, 1 Wall Street analyst forecast AFMD's earnings for 2026 to be -$13,277,798, with the lowest AFMD earnings forecast at -$13,277,798, and the highest AFMD earnings forecast at -$13,277,798.

In 2027, AFMD is forecast to generate -$10,327,176 in earnings, with the lowest earnings forecast at -$10,327,176 and the highest earnings forecast at -$10,327,176.

What is AFMD's revenue growth forecast for 2025-2027?

(NASDAQ: AFMD) Affimed Nv's forecast annual revenue growth rate of 140.43% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.41%.

Affimed Nv's revenue in 2025 is $932,978.On average, 2 Wall Street analysts forecast AFMD's revenue for 2025 to be $34,915,691, with the lowest AFMD revenue forecast at $12,130,334, and the highest AFMD revenue forecast at $57,701,047. On average, 1 Wall Street analysts forecast AFMD's revenue for 2026 to be $51,635,880, with the lowest AFMD revenue forecast at $51,635,880, and the highest AFMD revenue forecast at $51,635,880.

In 2027, AFMD is forecast to generate $228,591,223 in revenue, with the lowest revenue forecast at $61,143,439 and the highest revenue forecast at $396,039,007.

What is AFMD's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: AFMD) forecast ROA is -20.44%, which is lower than the forecast US Biotechnology industry average of 35.5%.

What is AFMD's Price Target?

According to 3 Wall Street analysts that have issued a 1 year AFMD price target, the average AFMD price target is $9.67, with the highest AFMD stock price forecast at $15.00 and the lowest AFMD stock price forecast at $4.00.

On average, Wall Street analysts predict that Affimed Nv's share price could reach $9.67 by Dec 12, 2025. The average Affimed Nv stock price prediction forecasts a potential upside of 1,217.03% from the current AFMD share price of $0.73.

What is AFMD's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: AFMD) Affimed Nv's current Earnings Per Share (EPS) is -$4.90. On average, analysts forecast that AFMD's EPS will be -$2.05 for 2025, with the lowest EPS forecast at -$3.02, and the highest EPS forecast at -$1.05. On average, analysts forecast that AFMD's EPS will be -$0.81 for 2026, with the lowest EPS forecast at -$0.81, and the highest EPS forecast at -$0.81. In 2027, AFMD's EPS is forecast to hit -$0.63 (min: -$0.63, max: -$0.63).

What is AFMD's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: AFMD) forecast ROE is -47.49%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.